DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,986 filers reported holding DANAHER CORPORATION in Q2 2023. The put-call ratio across all filers is 0.79 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $624,000,000 | -10.0% | 2,600,000 | -5.5% | 9.14% | -19.4% |
| Q1 2023 | $693,110,000 | -3.3% | 2,750,000 | +1.9% | 11.34% | -5.6% |
| Q4 2022 | $716,634,000 | +2.8% | 2,700,000 | 0.0% | 12.01% | -4.7% |
| Q3 2022 | $697,383,000 | +19.6% | 2,700,000 | +17.4% | 12.60% | -8.7% |
| Q2 2022 | $583,096,000 | -20.2% | 2,300,000 | -7.6% | 13.80% | +45.2% |
| Q1 2022 | $730,392,000 | -23.4% | 2,490,000 | -14.1% | 9.51% | +42.7% |
| Q4 2021 | $954,129,000 | +9.4% | 2,900,000 | +1.2% | 6.66% | +39.9% |
| Q3 2021 | $872,221,000 | +13.4% | 2,865,000 | 0.0% | 4.76% | +5.8% |
| Q2 2021 | $768,851,000 | +17.8% | 2,865,000 | -1.2% | 4.50% | +2.3% |
| Q1 2021 | $652,732,000 | -2.1% | 2,900,000 | -3.3% | 4.40% | -14.4% |
| Q4 2020 | $666,420,000 | +3.2% | 3,000,000 | 0.0% | 5.14% | -20.5% |
| Q3 2020 | $645,990,000 | +21.8% | 3,000,000 | 0.0% | 6.46% | -11.0% |
| Q2 2020 | $530,490,000 | +7.4% | 3,000,000 | -16.0% | 7.26% | -7.9% |
| Q1 2020 | $494,124,000 | -13.2% | 3,570,000 | -3.8% | 7.88% | +20.4% |
| Q4 2019 | $569,411,000 | +6.3% | 3,710,000 | 0.0% | 6.55% | +2.8% |
| Q3 2019 | $535,835,000 | +1.1% | 3,710,000 | 0.0% | 6.37% | +2.5% |
| Q2 2019 | $530,233,000 | +8.3% | 3,710,000 | 0.0% | 6.21% | +14.0% |
| Q1 2019 | $489,794,000 | +52.7% | 3,710,000 | +19.3% | 5.45% | +10.5% |
| Q4 2018 | $320,703,000 | -9.2% | 3,110,000 | -4.3% | 4.93% | +99.6% |
| Q3 2018 | $353,145,000 | +10.1% | 3,250,000 | 0.0% | 2.47% | +10.5% |
| Q2 2018 | $320,710,000 | +0.8% | 3,250,000 | 0.0% | 2.24% | -6.4% |
| Q1 2018 | $318,208,000 | +3.6% | 3,250,000 | -1.8% | 2.39% | +7.8% |
| Q4 2017 | $307,234,000 | +8.5% | 3,310,000 | +0.3% | 2.22% | -6.8% |
| Q3 2017 | $283,074,000 | +1.6% | 3,300,000 | 0.0% | 2.38% | -3.6% |
| Q2 2017 | $278,487,000 | +5.0% | 3,300,000 | +6.5% | 2.47% | -4.6% |
| Q1 2017 | $265,143,000 | +4.8% | 3,100,000 | -4.6% | 2.59% | +4.2% |
| Q4 2016 | $252,980,000 | -28.3% | 3,250,000 | -27.8% | 2.48% | -19.0% |
| Q3 2016 | $352,755,000 | -9.3% | 4,500,000 | +16.9% | 3.07% | -17.2% |
| Q2 2016 | $388,850,000 | +10.8% | 3,850,000 | +4.1% | 3.71% | +14.6% |
| Q1 2016 | $350,982,000 | +68.0% | 3,700,000 | +64.4% | 3.23% | +52.5% |
| Q4 2015 | $208,980,000 | +9.0% | 2,250,000 | 0.0% | 2.12% | +17.2% |
| Q3 2015 | $191,722,000 | – | 2,250,000 | – | 1.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 218,613 | $52,456,537 | 13.03% |
| Defender Capital, LLC. | 144,082 | $34,579,651 | 11.89% |
| CADEN CAPITAL PARTNERS, LP | 185,360 | $44,486,400 | 11.28% |
| BOONE CAPITAL MANAGEMENT LLC | 109,910 | $26,378,400 | 9.47% |
| Clio Asset Management LLC | 42,215 | $10,131,600 | 9.38% |
| Bancreek Capital Management, LP | 50,080 | $12,019,200 | 9.16% |
| Third Point | 2,600,000 | $624,000,000 | 9.14% |
| Consulta Ltd | 500,000 | $120,000,000 | 8.34% |
| Riverstone Advisors, LLC | 55,324 | $13,277,778 | 8.06% |
| York GP, Ltd. | 20,000 | $4,800,000 | 7.82% |